Phathom Pharmaceuticals (PHAT) Depreciation & Amortization (CF) (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Depreciation & Amortization (CF) of $114000.0 for Q2 2026, down 33.72% year-over-year from $172000.0 in Q2 2025, and up 3.64% quarter-over-quarter from $110000.0 in Q1 2026.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $114000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) fell 33.72% year-over-year to $114000.0; the TTM figure through Jun 2026 stood at $508000.0 (down 30.7% YoY), while the FY2025 annual figure was $633000.0, down 20.38% from the prior year.
- Depreciation & Amortization (CF) climbed to $114000.0 in Q2 2026 per PHAT's latest filing, from $110000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $214000.0 in Q1 2024 and bottomed at $110000.0 in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $158166.7 across 5 years, with a median of $162000.0 in 2022.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) soared 60.16% — and 2026, when it plunged 37.85%.
- Phathom Pharmaceuticals' Depreciation & Amortization (CF) stood at $168000.0 in 2022, then advanced by 10.12% to $185000.0 in 2023, then climbed by 4.32% to $193000.0 in 2024, then sank by 33.68% to $128000.0 in 2025, then dropped by 10.94% to $114000.0 in 2026.
- Business Quant data shows PHAT's Depreciation & Amortization (CF) at $114000.0 in Q2 2026, $110000.0 in Q1 2026, and $128000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn | 114,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 114,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Sep 30, 2025 | 156,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Dec 31, 2024 | 193,000.00 |
| Sep 30, 2024 | 191,000.00 |
| Jun 30, 2024 | 197,000.00 |
| Mar 31, 2024 | 214,000.00 |
| Dec 31, 2023 | 185,000.00 |
| Sep 30, 2023 | 121,000.00 |
| Jun 30, 2023 | 123,000.00 |
| Mar 31, 2023 | 146,000.00 |
| Dec 31, 2022 | 168,000.00 |
| Sep 30, 2022 | 175,000.00 |
| Jun 30, 2022 | 149,000.00 |
| Mar 31, 2022 | 128,000.00 |
| Dec 31, 2021 | 135,000.00 |
| Sep 30, 2021 | 130,000.00 |